Jeffrey S. Glenn, M.D., Ph.D.
Academic Appointments
- Associate Professor, Medicine - Gastroenterology & Hepatology
- Member, Stanford Cancer Institute
- Member, Bio-X
- Associate Professor, Microbiology & Immunology
Key Documents
Contact Information
-
Clinical Offices
Gastroenterology 269 Campus Dr. - CCSR Bldg Rm. 3115 MC: 5171 Stanford, CA 94305 Tel Work (650) 725-3373 Fax (650) 723-3032
- Academic Offices
Personal Information Email Tel (650) 725-3373Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Gastroenterology
Administrative Appointments
- Director, Center for Hepatitis and Liver Tissue Engineering (2006 - present)
Honors and Awards
- Summa cum laude, U.C. Berkeley (1984)
- Physician Postdoctoral Fellowship Award, Howard Hughes Medical Institute (1995-1998)
- Career Award, Burroughs Wellcome Fund (1998-2005)
- Clinical Scientist Award in Translational Research, Burroughs Wellcome Fund (2005-2010)
- Elected member, American Society for Clinical Investigation (2008)
- Regents Scholarship, U.C.S.F. (1984-1993)
Professional Education
| Internship: | Stanford University School of Medicine CA (1994) |
| Medical Education: | UCSF School of Medicine CA (1993) |
| Ph.D.: | U.C.S.F., Biochemistry and Biophysics (1992) |
| M.D.: | U.C.S.F., Medicine/MSTP (1993) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
Dr. Glenn's primary interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies. Current projects aim to better understand the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses-both as a mechanism of intracellular trafficking and trigger of virus assembly, and as a target for a promising antiviral treatment. The function and cell biology of the hepatitis C virus (HCV) non-structural proteins are also being studied. Here the focus is on identifying key determinants of pathogenesis and designing novel antiviral strategies. Other interests include exploitation of hepatic stem cells, development of a small animal model for HCV, and engineered human liver tissues.
Publications
- Role for ADP ribosylation factor 1 in the regulation of hepatitis C virus replication. J Virol. 2011; (2): 946-56
- Simplified RNA secondary structure mapping by automation of SHAPE data analysis. Nucleic Acids Res. 2011; (22): e151
- Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell. 2011; (4): 621-32
- The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology. 2011; (1): 10-8
- A small molecule inhibits HCV replication and alters NS4B's subcellular distribution. Antiviral Res. 2010; (1): 1-8
- Hydrophobic nanoparticles improve permeability of cell-encapsulating poly(ethylene glycol) hydrogels while maintaining patternability. Proc Natl Acad Sci U S A. 2010; (48): 20709-14
Help
Trial Administration